Johnson & Johnson has received separate subpoenas from US Attorney’s Offices in Philadelphia, Boston and San Francisco related to marketing of three prescription drugs.
The drugs at issue are schizophrenia and bipolar treatment Risperdal, marketed by Janssen, epilepsy treatment Topamax by Ortho-McNeil and heart-failure drug Natrecor by Scios.
The investigations have been previously disclosed.
The latest subpoenas seek information concerning corporate supervision and oversight of the J&J subsidiaries, which sell the drugs.
The new subpoenas arrived at J&J’s corporate headquarters late last week, according to published reports.
J&J said it plans to cooperate in responding to the subpoenas.